Brought to you by 
Atrix licenses Leuprogel rights to Sanofi-Synthelabo
27 Feb 2002
Executive Summary
In exchange for up to $60mm, drug delivery and development company Atrix Laboratories licensed exclusive US and Canadian rights to its advanced prostate cancer therapeutic candidate Leuprogel (leuprolide) to Sanofi-Synthelabo.
Deal Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com